Genetic Engineering of Bacteriophages Against Infectious Diseases

被引:117
作者
Chen, Yibao [1 ,2 ]
Batra, Himanshu [3 ]
Dong, Junhua [1 ,2 ]
Chen, Cen [1 ,2 ]
Rao, Venigalla B. [3 ]
Tao, Pan [1 ,2 ,3 ]
机构
[1] Huazhong Agr Univ, Coll Vet Med, Wuhan, Hubei, Peoples R China
[2] Huazhong Agr Univ, Cooperat Innovat Ctr Sustainable Pig Prod, Wuhan, Hubei, Peoples R China
[3] Catholic Univ Amer, Dept Biol, Washington, DC 20064 USA
基金
中国国家自然科学基金;
关键词
bacteriophages; genome engineering; vaccine platform; phage therapy; infectious disease; CRISPR-CAS; ESCHERICHIA-COLI; PHAGE THERAPY; HOST-RANGE; FILAMENTOUS BACTERIOPHAGE; PSEUDOMONAS-AERUGINOSA; ANTIBODY-RESPONSES; DENDRITIC CELLS; CLINICAL-TRIAL; VIRUS-LIKE;
D O I
10.3389/fmicb.2019.00954
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Bacteriophages (phages) are the most abundant and widely distributed organisms on Earth, constituting a virtually unlimited resource to explore the development of biomedical therapies. The therapeutic use of phages to treat bacterial infections ("phage therapy") was conceived by Felix d'Herelle nearly a century ago. However, its power has been realized only recently, largely due to the emergence of multi-antibiotic resistant bacterial pathogens. Progress in technologies, such as high-throughput sequencing, genome editing, and synthetic biology, further opened doors to explore this vast treasure trove. Here, we review some of the emerging themes on the use of phages against infectious diseases. In addition to phage therapy, phages have also been developed as vaccine platforms to deliver antigens as part of virus-like nanoparticles that can stimulate immune responses and prevent pathogen infections. Phage engineering promises to generate phage variants with unique properties for prophylactic and therapeutic applications. These approaches have created momentum to accelerate basic as well as translational phage research and potential development of therapeutics in the near future.
引用
收藏
页数:12
相关论文
共 138 条
[1]   Immunodominance: A pivotal principle in host response to viral infections [J].
Akram, Ali ;
Inman, Robert D. .
CLINICAL IMMUNOLOGY, 2012, 143 (02) :99-115
[2]   Engineering Modular Viral Scaffolds for Targeted Bacterial Population Editing [J].
Ando, Hiroki ;
Lemire, Sebastien ;
Pires, Diana P. ;
Lu, Timothy K. .
CELL SYSTEMS, 2015, 1 (03) :187-196
[3]  
[Anonymous], 2014, NIAIDS ANT RES PROGR
[4]  
[Anonymous], 2018, VIRUSES BASEL
[5]   Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns [J].
Bachmann, Martin F. ;
Jennings, Gary T. .
NATURE REVIEWS IMMUNOLOGY, 2010, 10 (11) :787-796
[6]   THE INFLUENCE OF ANTIGEN ORGANIZATION ON B-CELL RESPONSIVENESS [J].
BACHMANN, MF ;
ROHRER, UH ;
KUNDIG, TM ;
BURKI, K ;
HENGARTNER, H ;
ZINKERNAGEL, RM .
SCIENCE, 1993, 262 (5138) :1448-1451
[7]   The influence of virus structure on antibody responses and virus serotype formation [J].
Bachmann, MF ;
Zinkernagel, RM .
IMMUNOLOGY TODAY, 1996, 17 (12) :553-558
[8]   Genetically modified bacteriophages in applied microbiology [J].
Bardy, P. ;
Pantucek, R. ;
Benesik, M. ;
Doskar, J. .
JOURNAL OF APPLIED MICROBIOLOGY, 2016, 121 (03) :618-633
[9]   Strategies for Editing Virulent Staphylococcal Phages Using CRISPR-Cas10 [J].
Bari, S. M. Nayeemul ;
Walker, Forrest C. ;
Cater, Katie ;
Aslan, Barbaros ;
Hatoum-Aslan, Asma .
ACS SYNTHETIC BIOLOGY, 2017, 6 (12) :2316-2325
[10]   CRISPR provides acquired resistance against viruses in prokaryotes [J].
Barrangou, Rodolphe ;
Fremaux, Christophe ;
Deveau, Helene ;
Richards, Melissa ;
Boyaval, Patrick ;
Moineau, Sylvain ;
Romero, Dennis A. ;
Horvath, Philippe .
SCIENCE, 2007, 315 (5819) :1709-1712